Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Raw Materials (2020 - 2025)

Bioventus' Raw Materials history spans 6 years, with the latest figure at $21.2 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 3.88% year-over-year to $21.2 million; the TTM value through Dec 2025 reached $21.2 million, down 3.88%, while the annual FY2025 figure was $21.2 million, 3.88% down from the prior year.
  • Raw Materials reached $21.2 million in Q4 2025 per BVS's latest filing, down from $21.9 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $26.4 million in Q3 2023 to a low of $3.4 million in Q4 2021.
  • Average Raw Materials over 5 years is $18.8 million, with a median of $21.6 million recorded in 2025.
  • Peak YoY movement for Raw Materials: skyrocketed 414.05% in 2022, then dropped 11.23% in 2024.
  • A 5-year view of Raw Materials shows it stood at $12.2 million in 2021, then skyrocketed by 51.1% to $18.5 million in 2022, then rose by 14.13% to $21.1 million in 2023, then increased by 4.92% to $22.1 million in 2024, then decreased by 3.88% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Raw Materials are $21.2 million (Q4 2025), $21.9 million (Q3 2025), and $23.4 million (Q2 2025).